


In the Claims:

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims:

1. (Original) A compound of Formula (I),



Formula (I)

wherein

A represents a direct bond or optionally substituted C₁₋₅alkylene;


R¹ represents hydrogen; optionally substituted C₁₋₈alkyl; or (CH₂)_b-R^a,

wherein R^a represents C₃₋₈cycloalkyl and b is zero or an integer from 1 to 6;

R² represents an optionally substituted mono- or bi-cyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR³R^{3a}, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxy or halo;


R³ and R^{3a} are independently selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;

R^4 is selected from an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S; or a group of formula III-a; III-b; III-c; III-d; III-e; III-f, III-g, III-h, III-i, III-j or III-k;



wherein **het** represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 4 heteroatoms independently selected from O, N and S;

R^6 and R^{6a} , are selected from:

- (i) R^6 and R^{6a} are independently selected from hydrogen and optionally substituted C_{1-8} alkyl; or
- (ii) R^6 and R^{6a} together represent carbonyl; or
- (iii) R^6  $A-N-R^7$ represents an optionally substituted 3- to 8- membered heterocyclic ring containing from 1 to 3 further heteroatoms independently selected from O, N and S, and R^{6a} represents hydrogen and optionally substituted C_{1-8} alkyl; R^7 represents hydrogen or optionally substituted C_{1-8} alkyl;

R⁸ are selected from: : C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl and heterocyclyl wherein **R⁸** is optionally substituted with halo, hydroxy, amino, NO₂, cyano, C₁₋₄alkanoyloxy, N-C₁₋₄alkylamino, N,N-di-C₁₋₄alkylamino, HO-C₂₋₄alkyl-NH-, HO-C₂₋₄alkyl-N(C₁₋₄alkyl)-, -S(O_n)-C₁₋₄alkyl, -N(R)S(O_n)-C₁₋₄alkyl, -S(O_n)N(R)-C₁₋₄alkyl or heterocyclyl optionally substituted by C₁₋₄alkyl, C₂₋₄alkenyl or C₂₋₄alkynyl, wherein **R** is hydrogen or C₁₋₄alkyl;

R⁹ is selected from:

- (i) **R⁹** represents hydrogen, aryl, a 3- to 10 membered heterocyclic ring or optionally-substituted C₁₋₈alkyl; and
- (ii) the structure N(**R⁹R¹⁰**) represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S;


R¹⁰ meets the definition in option (ii) for **R⁹** above or when **R⁹** meets the definition in option (i) above **R¹⁰** represents hydrogen or optionally substituted C₁₋₈alkyl;

R¹² and **R^{12a}** are selected from:

- (i) **R¹²** and **R^{12a}** are independently selected from hydrogen or optionally substituted C₁₋₈alkyl; or
- (ii) **R¹²** and **R^{12a}** together with the carbon to which they are attached form an optionally substituted 3 to 7-membered cycloalkyl ring;


R¹³ and **R¹⁴** are selected from:

- (i) **R¹³** is selected from hydrogen; optionally substituted C₁₋₈alkyl; optionally substituted aryl; -**R^d**-Ar, where **R^d** represents C₁₋₈alkylene and Ar represents optionally substituted aryl; and optionally substituted 3- to 8- membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; and **R¹⁴** is selected from hydrogen; optionally substituted C₁₋₈alkyl and optionally substituted aryl;


- (ii) wherein R^4 represents a group of formula **III-a**, **III-b** or **III-i**, then the group $NR^{13}(-R^{14})$ represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S; or
- (iii) wherein R^4 represents structure **III-e**,  represents an optionally substituted 3- to 8-membered heterocyclic ring optionally containing from 1 to 4 heteroatoms independently selected from O, N and S;
 n is 0 to 2;
 or a salt, pro-drug or solvate thereof.

2. (Original) A compound according to Claim 1 wherein R^9 represents hydrogen, optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally-substituted C_{1-8} alkyl and R^{10} represents hydrogen or optionally substituted C_{1-8} alkyl wherein the optional substituents on aryl, the heterocyclic ring and C_{1-6} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8-membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$, $-S(O_{0-2})R^b$, wherein R^b and R^c are as in Claim 1.
3. (Original) A compound according to Claim 2 wherein R^9 is a C_{1-6} alkyl group substituted by pyridyl, thienyl, piperidinyl, imidazolyl, triazolyl, thiazolyl, pyrrolidinyl, piperazinyl, morpholinyl, imidazolinyl, benztriazolyl, benzimidazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, oxazolyl, furanyl, pyrrolyl, 1,3-dioxolanyl or 2-azetiny, each of which is optionally substituted.


4. (Original) A compound according to Claim 1 wherein the structure $N(R^9R^{10})$ represents an optionally-substituted 3- to 10 membered heterocyclic ring optionally containing from 1 to 3 further heteroatoms independently selected from O, N and S.
5. (Original) A compound according to Claim 4 wherein the 3- to 10 membered heterocyclic ring is optionally substituted by one of more groups selected from R^{15} wherein R^{15} is selected from optionally substituted aryl, an optionally substituted 3- to 10 membered heterocyclic ring or optionally substituted C_{1-4} alkyl wherein the optional substituents on aryl, a heterocyclic ring or C_{1-6} alkyl are selected from: hydroxy, amino, nitro, cyano, optionally-substituted aryl, optionally substituted 3- to 8- membered heterocyclyl containing from 1 to 4 heteroatoms independently selected from O, N and S, $-O-R^b$, $C(O)NR^bR^c$, $-NR^bR^c$, $-NR^cC(O)-R^b$, $-C(O)NR^bR^c$, $-NR^cS(O_{0-2})R^b$, $-S(O_{0-2})R^b$, wherein R^b and R^c are as defined in Claim 1.
6. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R^4 is selected from a group of formula III-a , III-g, III-h, III-i, III-j or III-k:




III-a




III-g




III-h



III-i



III-j



III-k

67. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein X and R⁸ represent either:-
 (a) X represents N and R⁸ represents cyano or -C(O)O-R^b; or
 (b) X represents N and R⁸ represents hydrogen.
78. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R² is selected from an optionally substituted monocyclic aromatic ring structure wherein the optional substituents are selected from cyano, NR^eR^f, optionally substituted C₁₋₈alkyl, optionally substituted C₁₋₈alkoxy or halo wherein R^e and R^f are independently selected from hydrogen, C₁₋₆alkyl or aryl.
89. (Currently amended) A compound according to claim 1 ~~any one of the preceding claims~~ wherein R¹ is hydrogen.
910. (Currently amended) A compound selected from:
 isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate;
 isopropyl [(1*E*)-({(2*S*)-2-[5-[2-(7-azabicyclo[2.2.1]hept-7-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]carbamate;
 and
 2-[(1*E*)-({(2*S*)-2-[5-[2-(2-azabicyclo[2.2.2]oct-2-yl)-1,1-dimethyl-2-oxoethyl]-2-(3,5-dimethylphenyl)-1*H*-indol-3-yl]propyl} amino)(3-pyridin-4-ylpyrrolidin-1-yl)methylene]amino}carbonyl)oxy]-2-methylpropyl acetate
 or a salt, pro-drug or solvate thereof.


~~1011.~~ (Cancelled)

~~1112.~~ (Currently amended) A pharmaceutical formulation comprising a compound, or salt, pro-drug or solvate thereof, according to claim 1 ~~any one of Claims 1 to 9~~ and a pharmaceutically acceptable diluent or carrier.


~~1213.~~ (Currently amended) A method of treating and/or preventing a sex hormone related condition in a patient, the method comprising administering ~~Use of a compound according to claim 1, or salt, pro-drug or solvate thereof, according to to the patient, any one of Claims 1 to 9, in the manufacture of a medicament for administration to a patient, for therapeutically treating and/or preventing a sex hormone-related condition in the patient.~~

~~1314.~~ (Currently amended) A process of producing a compound, or salt, pro-drug or solvate thereof, according to Claim 1, wherein the process comprises a reaction step selected from any one of steps (a) to (b):-

(a) Reaction of a compound of formula **XXXII** as follows



(b) Reaction of a compound of Formula XXXIV as follows



and thereafter if necessary:

- i) converting a compound of the Formula (I) into another compound of the Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate.